Slide 1: Annual General Meeting
For personal use only Annual General Meeting Tuesday 25 October 2011 1
Slide 2: Business Segments
Business Segments For personal use only • Clinical drug trials – Customers are pharma / biotech companies – Quantify the effects of drugs on human subjects in clinical trials • Sport – Customers are athletes, parents, schools, doctors, sports teams or sporting associations – Quick and efficient web
Slide 3: Year to 30 June 2011 - Highlights
Year to 30 June 2011 - Highlights For personal use only • FX fluctuations impacted on both revenue margins and profitability • Overall result showed a breakeven result for the operating business and a Net Loss After Tax of A$0.85m, including: – Loss from Axon Sports A$0.63m – FX loss A$0.20m • Secon
Slide 4: FY 2011 - Clinical Trial Sales Contracts
FY 2011 - Clinical Trial Sales Contracts For personal use only • US$9.3m sales contracts signed, an improvement of 5.4% on the previous year CogState Clinical Trial Sales Contracts US$ 10,000,000 9,000,000 8,000,000 7,000,000 6,000,000 5,000,000 4,000,000 3,000,000 2,000,000 1,000,000 - FY 2005 FY 2
Slide 5: Improved Performance – 2nd Half Year
Improved Performance – 2nd Half Year For personal use only • Record level of sales contracts signed: H2 • H1: US$3.8m H2: US$5.5m No. CogState Sales Contracts Signed, by half year US$ 6,000 5,000 4,000 3,000 2,000 1,000 - H1 FY08 H2 FY08 H1 FY09 H2 FY09 H1 FY10 H2 FY10 HI FY11 H2 FY11 5
Slide 6: FY 2011 - Clinical Trial Revenue
FY 2011 - Clinical Trial Revenue For personal use only • A$8.1m revenue, a 14% reduction on previous year including currency impact • In constant currency, the reduction in revenue was 3% CogState Sales Revenue A$ vs US$ 10,000 8,000 Sales Revenue 6,000 A$ #039;000 4,000 US$ 2,000 0 FY2008 FY2009 FY201
Slide 7: Cost Reduction Strategies Implemented
Cost Reduction Strategies Implemented For personal use only • June 2011 cost reduction initiative • Restructure reduced headcount by 13 people • Annual cost saving of over $1m, inclusive of wages and on-costs • $0.2m of restructure costs fully expensed in June 2011 • Approx $0.35m of USA based wage
Slide 8: FY2012 – Sales Contracts
FY2012 – Sales Contracts For personal use only • Clinical trials sales contracts – US$4.0m of sales contracts signed since 1 Jul 2011 until today (Previous Corresponding Period : US$1.9m, up 110%) – US$9.5m of sales contracts signed since 1 Jan 2011 (PCP : US$5.2m, up 83%) • Contracted future income
Slide 9: FY2012 – Results To Date
FY2012 – Results To Date For personal use only • FY 2012 Revenue – A$2.2m revenue recorded in Q1 (PCP : A$1.6m, up 38%) – Additional revenue of A$4.2m already secured by contract (PCP : A$2.8m, up 50%) – Therefore, A$6.4m revenue already secured (PCP : A$4.4m, up 45%) • Foreign Exchange – FX gain fo
Slide 10: FY2012 – First Half Guidance
FY2012 – First Half Guidance For personal use only • At this time, we can confidently forecast a good result for the first half: – Strong revenue growth, approx in line with Q1 growth – Profit from operations (including Axon Sports operating result) – Net Profit After Tax (increased after accounting
Slide 11: Axon Sports Acquisition
Axon Sports Acquisition For personal use only Investment Rationale • Acquisition of the remaining 50% was important to secure 100% ownership of all intellectual property to allow CogState to actively pursue the opportunity for widespread community screening for dementia • Market opportunity in sport
Slide 12: Community Dementia Screening
Community Dementia Screening For personal use only • Community dementia screening represents the largest market opportunity by far for CogState technology • According to “World Alzheimer’s Report 2011*”: – It is estimated that globally 38m people are currently living with AD – Perhaps as many as 28m
Slide 13: Community Dementia Screening
Community Dementia Screening For personal use only • Large number of pharma companies in late stage development of possible disease modifying drugs, with some results expected as early as 2012 • Globally there is significant research $ being spent in area of AD biomarkers • Both disease modifying dr
Slide 14: Guiding decision making in clinical trials.
Guiding decision making in clinical trials. For personal use only CogState clinical trials systems used in more than 200 industry sponsored trials NK3 Olanz placebo 14
Slide 15: Guiding decision making in clinical trials
Guiding decision making in clinical trials CogState clinical trials systems used in more than 200 industry sponsored trials For personal use only 15
Slide 16: Guiding decision making in sports injury
Guiding decision making in sports injury For personal use only 16
Slide 17: Guiding decision making in sports injury
Guiding decision making in sports injury For personal use only 17
Slide 18: Guiding decision making in dementia screening
Guiding decision making in dementia screening For personal use only Monitoring memory using CogState can detect Alzheimer pathology 18
Slide 19: Guiding decision making in dementia screening
Guiding decision making in dementia screening For personal use only Performance on CogState associated with Alzheimer pathology in AIBL 19